Sponsors & Exhibitors
CooperSurgical Fertility and Genomic Solutions
CooperSurgical Fertility and Genomic Solutions is the global leader in IVF and reproductive genetics, providing innovative products and services for every step in the ART journey. Building on the high-quality reputation of our legacy companies ORIGIO, SAGE, Humagen, The Pipette Company (TPC), K-Systems, Research Instruments (RI), Wallace®, LifeGlobal® and CooperGenomicsTM, we provide a trusted system of consumables, equipment, technologies and genetic testing.
With an unmatched product breadth, scientific knowledge and geographical reach, our approach opens the door to extensive partnership possibilities for the future through tailored product solutions, world-class evidence-based training, and organizing expert-led workshops.
Illumina is the leading technology provider for noninvasive prenatal testing (NIPT)—enabling health care professionals and expectant parents to be informed about their pregnancy. Illumina is dedicated to improving health through genomics.
IBSA Genetics is a division of IBSA Institut Biochimique SA, devoted to the development of technologically advanced solutions for genetic testing in cytogenetics and IVF.
IBSA Genetics combines its unique scientific and technological expertise with the collaboration with some of the world’s leading IVF centers.
IBSA Genetics developed Chromoscreen®, a novel microarray-based test for Preimplantation Genetic Screening to assess the chromosome arrangement in embryos before implantation in IVF. It includes everything is required to investigate aneuploidies in polar bodies, blastomeres and trophectoderm cells.
IBSA Genetics also developed Chromoscreen Software®, a bioinformatic tool for array analysis, samples management and patient tracking.
IBSA Institut Biochimique SA
Via del Piano, P.O. Box 266,
Tel: +41 58 360 10 00
Fax: +41 58 360 16 47
Web: www.chromoscreen.com; www.ibsagroup.com
PerkinElmer is a global company focused on improving the health and safety of people and their environment. Within the field of fetal and maternal healthcare, PerkinElmer offers complete screening solutions including instrumentation, reagents and risk calculation software for early detection of pregnancy related anomalies*. Annually, more than 10 million prenatal risk assessments are made on the basis of PerkinElmer tests.
PerkinElmer is developing the Vanadis® NIPT system which is an automated non-sequencing, non-PCR based solution for cfDNA analysis. PerkinElmer will in the future offer an easy to use, cost-effective, high-throughput screening test to help facilitate wider access to non-invasive prenatal testing for pregnant women.
*Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.
Contact : Ms. Tytti Massinen
Agilent Technologies Inc.
Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers’ most challenging questions. The company generated revenues of $4.47 billion in fiscal 2017 and employs 14,200 people worldwide. Information about Agilent is available at www.agilent.com.
3 Avenue du Canada
CS 90263, 91978
LES ULIS Cedex
Tel: 01 64 53 60 00
Celmatix is a next-generation women’s health company transforming reproductive health care through genomics and big data. The company’s research-driven products include the Fertilome® genetic test, the world’s first multigene panel test for a woman’s reproductive health and fertility, and Polaris®, a real-time predictive analytics platform which helps physicians optimize patient outcomes and improve the patient experience. Learn more at www.celmatix.com.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche Sequencing Solution of Roche is focused on developing novel technologies and products to support innovation in clinical research applications. Part of Roche Sequencing Solutions, the Harmony® prenatal test is a non-invasive screening test for pregnant women that can be used as early as 10 weeks of pregnancy. By evaluating fetal cell-free DNA found in maternal blood, including accurate measurement of the fetal fraction of cfDNA, the test assesses the probability of Trisomy 21 (Down syndrome) and other common fetal chromosomal conditions. The results are intended for prenatal screening and are not intended to be the sole basis for diagnosis. The Harmony® prenatal test has been used to guide clinical care in over 1,400,000 pregnancies worldwide. For more information, visit www.harmonytest.com.